|
(P1036) |
C57BL/6 Programmed Death 1 (PD-1) knockout mouse shows autoantibody formation against cardiomyocytes but no impairment in functional integrity of the cardiovascular system |
| |
|
L. Michel, U. Hendgen-Cotta, I. Helfrich, T. Rassaf, M. Totzeck (Essen) |
|
(P1037) |
Improvement of virus-induced acute and chronic myocarditis models by use of miR-375 regulated coxsackievirus B3 |
| |
|
S. Pinkert, M. Pryshliak, K. Knoch, K. Klingel, A. Hazini, A. Beling, H. Fechner (Berlin, Dresden, Tübingen) |
|
(P1038) |
Treatment of coxsackievirus B3-infected mice with a soluble receptor molecule inhibits development of virus-mediated inflammatory cardiomyopathy |
| |
|
S. Pinkert, B. Dieringer, R. Klopfleisch, K. Pappritz, S. Van Linthout, M. Pryshliak, C. Tschöpe, K. Klingel, J. Kurreck, A. Beling, H. Fechner (Berlin, Tuebingen) |
|
(P1039) |
Immunomodulatory treatment reduces cytotoxic cells in patients with virus-negative inflammatory cardiomyopathy resulting in an improvement of LVEF in long-term follow-up: A 10 years observation study. |
| |
|
F. Escher, U. Kühl, D. Lassner, W. Poller, B. Pieske, H.-P. Schultheiss (Berlin) |
|
(P1040) |
PGE2-dependent MEF2-activation in an inflammatory cardiomyopathy |
| |
|
R. Schell, P. Theis, C. Haslinger, F. Alban, H. A. Katus, J. Backs (Heidelberg) |
|
(P1041) |
Regulation of MMP activity influences cardiac fibrosis and cardiac inflammation during viral myocarditis |
| |
|
D. Lindner, P. M. Becher, B. Stoffers, S. Hinrichs, M. Schwarzl, L. Bacmeister, K. Klingel, S. Blankenberg, D. Westermann (Hamburg, Tübingen) |